Literature DB >> 20053870

Autoimmunity and the risk of myeloproliferative neoplasms.

Sigurdur Y Kristinsson1, Ola Landgren, Jan Samuelsson, Magnus Björkholm, Lynn R Goldin.   

Abstract

The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of myeloproliferative neoplasm. We found a prior history of any autoimmune disease to be associated with a significantly increased risk of myeloproliferative neoplasms (odds ratio (OR)=1.2; 95% confidence interval (CI) 1.0-1.3; P=0.021). Specifically, we found an increased risk of MPNs associated with a prior immune thrombocytopenic purpura (2.9; 1.7-7.2), Crohn's disease (1.8; 1.1-3.0), polymyalgia rheumatica (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter's syndrome (15.9; 1.8-142) and aplastic anemia (7.8; 3.7-16.7). The risk of myeloproliferative neoplasms associated with prior autoimmune diseases is modest but statistically significant. Future studies are needed to unravel the effects of these autoimmune diseases themselves, their treatment, or common genetic susceptibility.

Entities:  

Mesh:

Year:  2010        PMID: 20053870      PMCID: PMC2895049          DOI: 10.3324/haematol.2009.020412

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  Autoimmunity and risk for Hodgkin's lymphoma by subtype.

Authors:  Sigurdur Y Kristinsson; Ola Landgren; Jan Sjöberg; Ingemar Turesson; Magnus Björkholm; Lynn R Goldin
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

3.  The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain.

Authors:  M A Gonzalez-Gay; C Garcia-Porrua; C Salvarani; I Olivieri; G G Hunder
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

Review 4.  Development of polycythemia vera and chronic lymphocytic leukemia during the course of refractory idiopathic thrombocytopenic purpura.

Authors:  G Wang; Y S Ahn; C C Whitcomb; W J Harrington
Journal:  Cancer       Date:  1984-04-15       Impact factor: 6.860

5.  No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls.

Authors:  Geirmund Myklebust; Tom Wilsgaard; Bjarne Koster Jacobsen; Jan Tore Gran
Journal:  J Rheumatol       Date:  2002-10       Impact factor: 4.666

6.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

7.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

8.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

9.  Cancer risks in Crohn disease patients.

Authors:  K Hemminki; X Li; J Sundquist; K Sundquist
Journal:  Ann Oncol       Date:  2008-09-02       Impact factor: 32.976

10.  Risks of myeloid malignancies in patients with autoimmune conditions.

Authors:  L A Anderson; R M Pfeiffer; O Landgren; S Gadalla; S I Berndt; E A Engels
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more
  59 in total

1.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Lynn R Goldin; Sigurdur Y Kristinsson; Xueying Sharon Liang; Asa R Derolf; Ola Landgren; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

Review 3.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

4.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

5.  Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Authors:  M Massa; V Rosti; R Campanelli; G Fois; G Barosi
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

Review 6.  Impact of inflammation on early hematopoiesis and the microenvironment.

Authors:  Hitoshi Takizawa; Markus G Manz
Journal:  Int J Hematol       Date:  2017-05-30       Impact factor: 2.490

7.  Association between rheumatic diseases and cancer: results from a clinical practice cohort study.

Authors:  Mattia Bellan; Enrico Boggio; Daniele Sola; Antonello Gibbin; Alessandro Gualerzi; Serena Favretto; Giulia Guaschino; Ramona Bonometti; Roberta Pedrazzoli; Mario Pirisi; Pier Paolo Sainaghi
Journal:  Intern Emerg Med       Date:  2017-02-08       Impact factor: 3.397

8.  Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.

Authors:  Alexis D Leal; Carrie A Thompson; Alice H Wang; Robert A Vierkant; Thomas M Habermann; Julie A Ross; Ruben A Mesa; Beth A Virnig; James R Cerhan
Journal:  Int J Cancer       Date:  2013-10-15       Impact factor: 7.396

Review 9.  Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.

Authors:  Laura F Mendez Luque; Amanda L Blackmon; Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 10.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.